Business Wire

TX-SONAR

10.6.2024 15:01:28 CEST | Business Wire | Press release

Share
Sonar and AWS Expand Collaboration to Drive Adoption of Clean Code Practices

Sonar, the leader in Clean Code solutions, today announced the expansion of its collaboration with Amazon Web Services (AWS) to help enterprises achieve high-quality code that is clean. SonarCloud, Sonar’s SaaS offering, will be available as an integration with Amazon CodeCatalyst, a unified software development service. Additionally, SonarCloud is now certified by the AWS Foundational Technical Review (FTR) – a set of guidelines to reduce risks around security, reliability, and operational excellence, as defined by the AWS Well-Architected Framework.

“With SonarCloud we enabled our engineering teams to drive consistent code quality and standards across the whole organization. The easy integration into our development toolchain and the simple UI allow us to scale fast and without any issues. The wide adoption and the excellent customer support help you overcome any difficulties,” said Andre Ostermeier, Lead Solutions Architect at Relayr. “Besides that, SonarCloud is an excellent tool to drive Engineering KPIs and should not be underestimated by IT leaders.”

SonarCloud and Amazon CodeCatalyst: Improving Development Processes

Amazon CodeCatalyst features blueprint capabilities that allow customers to automatically set up everything they need to start a new software development project, including continuous integration and delivery (CI/CD) pipelines, deployable code, issue tracking, and fully configured AWS services.

“Customers building apps need to release code early and often, and with solid DevOps practices and tools,” said Nicolas Pujol, ISV Partner Management Leader in EMEA, AWS. “Sonar has done a great job giving developers and DevOps leaders solutions to be more productive, and we’re excited to collaborate to make these tools available to AWS customers.”

Amazon CodeCatalyst paired with Sonar’s unique Clean as You Code approach, delivered through SonarCloud, empowers developers to spend more time writing innovative code and less time managing local development environments. With SonarCloud integrated into Amazon CodeCatalyst CI/CD workflows, development teams can more easily ensure that only clean code will be added to their code base, improving the overall quality of the code written.

Sonar Puts Customer Experience First

Sonar achieved the AWS Foundational Technical Review (FTR) certification by demonstrating that SonarCloud meets best practices critical for a customer’s success. SonarCloud allows for shared expectations across teams rooted in clean code practices, automates code quality checks, and provides extensive feedback for issue resolution.

Sonar’s Clean as You Code Approach

The Clean as You Code approach enables developers and organizations to improve development velocity, code quality, and code security. This simple yet powerful methodology progressively improves the overall quality of the entire codebase as the code is written, with minimal cost and effort. Clean as You Code puts developers in the driver's seat where they take full ownership of the quality of the code they write.

“An increasing number of developers are writing code and building apps in the cloud. We created SonarCloud to provide these developers an easy way to achieve a state of Clean Code, designing a tool that seamlessly integrates with DevOps platforms,” said Fabrice Bellingard, VP of Products at Sonar. “Our growing collaboration with AWS will help more cloud-based development teams create high-quality code with our unique Clean as You Code methodology.”

Today, SonarCloud has over 100,000 active users. The solution has helped a wide range of organizations clean over 2.5 billion lines of code. SonarCloud is free to use on open-source projects. To learn more about SonarCloud, visit here.

About Sonar

Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.

To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240610167595/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye